Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 7/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1121822 | 0.82 | HPGD (0.60) | SMN1; SMN2ALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL3121683 | 0.81 | HPGD (0.58) | SMN1; SMN2ALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL18430420 | 0.80 | HPGD (0.62) | SMN1; SMN2ALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL2182641 | 0.79 | HPGD (0.61) | SMN1; SMN2ALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL18430419 | 0.79 | HPGD (0.61) | SMN1; SMN2ALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL22775116 | 0.78 | HPGD (0.56) | SMN1; SMN2ALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL6408001 | 0.77 | HPGD (0.54) | SMN1; SMN2ALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL21797959 | 0.77 | HPGD (0.55) | SMN1; SMN2ALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL18430429 | 0.77 | HPGD (0.58) | SMN1; SMN2ALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL7217593 | 0.76 | HPGD (0.76) | SMN1; SMN2ALDH1A1RAB9AHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| EP-0140540-B1 | PHOTOCHROMIC COMPOUNDS AND THEIR USES IN PHOTOREACTIVE LENSES | THE PLESSEY COMPANY plc (GB) | 1990-05-09 | — | — | EP | disclosed |
| US-4685783-A | Polychromic tetracyclo-spiro-adamatylidene derivatives, and polychromic lens incorporating said compounds | THE PLESSEY COMPANY P.L.C. (GB) | 1987-08-11 | — | — | US | disclosed |
| EP-0140540-A2 | Photochromic compounds and their uses in photoreactive lenses | THE PLESSEY COMPANY plc (GB) | 1985-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | SARS1, MAVS, ZC3HAV1 | SMN1; SMN2 992/4885ALDH1A1 4133/4885NPC1 2750/4885 |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | SMN1; SMN2 756/4885ALDH1A1 3714/4885NPC1 2197/4885 |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | MAVS, SARS1, ZC3HAV1 | SMN1; SMN2 756/4885ALDH1A1 3714/4885NPC1 2197/4885 |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | SMN1; SMN2 756/4885ALDH1A1 3714/4885NPC1 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.